Xiao Lei, Gu Shuntong, Chen Yonghui, Zhang Xiujun, Wang Yuqiang, Dai Xiangchen
Department of Vascular Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Department of Vascular Surgery, Tianjin Hospital, Tianjin, China.
J Endovasc Ther. 2023 Nov 18:15266028231209932. doi: 10.1177/15266028231209932.
This study aimed to compare midterm efficacy between drug-coated balloon (DCB) and bare metal stent (BMS) in the treatment of TASCII C/D femoropopliteal artery lesions.
The clinical data of patients with TASCII C/D femoropopliteal artery disease admitted to 3 vascular surgery centers from January 2018 to January 2021 were retrospectively analyzed. Patients were divided into DCB group and BMS group. The DCB group was further subdivided into DCB alone subgroup and DCB+BMS subgroup. Study primary outcomes were freedom from clinical-driven target lesion reintervention (FCD-TLR) at 24 months postprocedure. Secondary outcomes included ankle brachial index (ABI), Rutherford classification, major amputation rate, and mortality.
A total of 410 consecutive patients were enrolled. At 24 months follow-up, in DCB group (114 patients) relative to BMS group (296 patients), FCD-TLR (86.00% vs 71.91%, p=0.039), and ABI (0.53±0.11 vs 0.47±0.19, p=0.007) were higher; mean Rutherford class was lower (1.57±0.68 vs 3.31±1.39, p=0.000); and major amputation rate (0.87% vs 4.05%, p>0.05) and all-cause mortality (8.92% vs 6.41%, p>0.05) were statistically similar. In DCB alone, subgroup relative to DCB+BMS subgroup, FCD-TLR (90.00% vs 85.00%, p>0.05), major amputation rate (0 vs 1.08%, p>0.05), and all-cause mortality rate (9.09% vs 8.69%, p>0.05) were statistically similar, while FCD-TLR was higher in the DCB+BMS subgroup (90.00% vs 71.91%, p=0.045).
At midterm follow-up of patients treated for TASCII C/D femoropopliteal artery disease, use of DCB or of DCB combined with rescue BMS appeared similarly efficacious, and yielded more favorable outcomes than use of BMS.
The efficacy of drug-coated balloons relative to that of bare metal stents for the treatment of complex femoropopliteal artery lesions, particularly TASCII grade D lesions, remains uncertain. There is a scarcity of multicenter comparative studies, and in this multicenter retrospective study with up to 24-month follow-up, use of drug-coated balloon alone or combined with rescue bare metal stent appeared similarly efficacious while yielding more favorable outcomes than use of bare metal stent alone in the treatment of TASCII grade C/D femoropopliteal artery lesions. Randomized studies are warranted.
本研究旨在比较药物涂层球囊(DCB)与裸金属支架(BMS)治疗跨大西洋协作组(TASCII)C/D级股腘动脉病变的中期疗效。
回顾性分析2018年1月至2021年1月期间在3个血管外科中心收治的TASCII C/D级股腘动脉疾病患者的临床资料。患者分为DCB组和BMS组。DCB组进一步细分为单纯DCB亚组和DCB+BMS亚组。研究的主要结局是术后24个月无临床驱动的靶病变再次干预(FCD-TLR)。次要结局包括踝肱指数(ABI)、卢瑟福分级、大截肢率和死亡率。
共纳入410例连续患者。在24个月随访时,DCB组(114例患者)相对于BMS组(296例患者),FCD-TLR更高(86.00%对71.91%,p=0.039),ABI更高(0.53±0.11对0.47±0.19,p=0.007);平均卢瑟福分级更低(1.57±0.68对3.31±1.39,p=0.000);大截肢率(0.87%对4.05%,p>0.05)和全因死亡率(8.92%对6.41%,p>0.05)在统计学上相似。在单纯DCB亚组相对于DCB+BMS亚组中,FCD-TLR(90.00%对85.00%,p>0.05)、大截肢率(0对1.08%,p>0.05)和全因死亡率(9.09%对8.69%,p>0.05)在统计学上相似,而DCB+BMS亚组的FCD-TLR更高(90.00%对71.91%,p=0.045)。
在接受TASCII C/D级股腘动脉疾病治疗患者的中期随访中,使用DCB或DCB联合补救性BMS似乎疗效相似,且比使用BMS产生更有利的结果。
药物涂层球囊相对于裸金属支架治疗复杂股腘动脉病变,特别是TASCII D级病变的疗效仍不确定。多中心比较研究较少,在这项长达24个月随访的多中心回顾性研究中,单独使用药物涂层球囊或联合补救性裸金属支架在治疗TASCII C/D级股腘动脉病变时似乎疗效相似,同时比单独使用裸金属支架产生更有利的结果。有必要进行随机研究。